**Supplementary Table 2. Diagnostic performance of the three non-invasive tests for significant fibrosis (≥S2)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Number of cardiometabolic risk factors** | | **Cutoff** | **Sensitivity** | **Specificity** | **Positive predictive value** | **Negative predictive value** |
|  | **Fibrosis-4 index** | | | | | |
| **0** | | 1.26 | 57.5 | 87.8 | 84.4 | 64.3 |
| **1-3** | | 1.26 | 45.3 | 79.0 | 65.0 | 62.6 |
| **4-5** | | 0.80 | 80.0 | 43.8 | 59.7 | 67.7 |
|  | **Aspartate aminotransferase-to-platelet ratio index** | | | | | |
| **0** | | 0.56 | 66.0 | 82.9 | 81.6 | 68.0 |
| **1-3** | | 0.39 | 69.2 | 58.8 | 59.2 | 68.9 |
| **4-5** | | 0.54 | 50.0 | 79.2 | 71.4 | 60.3 |
|  | **NAFLD fibrosis score** | | | | | |
| **0** | | -3.55 | 83.0 | 53.7 | 67.2 | 73.3 |
| **1-3** | | -2.15 | 54.2 | 66.9 | 58.5 | 62.9 |
| **4-5** | | -1.00 | 48.0 | 70.8 | 63.2 | 56.7 |

NAFLD, non-alcoholic fatty liver disease.